Donglin Yan

6PUBLICATIONS
36CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical biotechnology diagnostics (incl. biosensors)Molecular targetsNeurogenetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 28, 2026
Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).

|Feb 27, 2026
A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer.

Connie D Cao, Joseph Robert McCorkle, Donglin Yan

|Jan 15, 2026
Assessing the Value of Sequential Next-Generation Sequencing and Multiple Molecular Tumor Board Reviews for Patients With Solid-Tumor Malignancies.

Allison L Swiecki-Sikora, Lydia Williams, Ning Li

|Sep 30, 2024
Phase I clinical trial designs in oncology: A systematic literature review from 2020 to 2022.

Ning Li, Xitong Zhou, Donglin Yan

|Sep 11, 2024
Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports.

Taylor A Rives, James Collard, Ning Li

|May 13, 2023
A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer.

Zin W Myint, William H St Clair, Stephen E Strup

Pageof 1

Frequent Collaborators

3 joint publications

Rachel W Miller

2 joint publications

Ning Li

2 joint publications

Derek B Allison

2 joint publications

Frederick R Ueland